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ABSTRACT
In cultured cancer cells the E3 ubiquitin ligase Rad18
activates Trans-Lesion Synthesis (TLS) and the Fan-
coni Anemia (FA) pathway. However, physiological
roles of Rad18 in DNA damage tolerance and carcino-
genesis are unknown and were investigated here.
Primary hematopoietic stem and progenitor cells
(HSPC) co-expressed RAD18 and FANCD2 proteins,
potentially consistent with a role for Rad18 in FA
pathway function during hematopoiesis. However,
hematopoietic defects typically associated with fanc-
deficiency (decreased HSPC numbers, reduced en-
graftment potential of HSPC, and Mitomycin C (MMC)
-sensitive hematopoiesis), were absent in Rad18−/−
mice. Moreover, primary Rad18−/− mouse embry-
onic fibroblasts (MEF) retained robust Fancd2 mono-
ubiquitination following MMC treatment. Therefore,
Rad18 is dispensable for FA pathway activation in
untransformed cells and the Rad18 and FA pathways
are separable in hematopoietic cells. In contrast with
responses to crosslinking agents, Rad18−/− HSPC
were sensitive to in vivo treatment with the myelo-
suppressive agent 7,12 Dimethylbenz[a]anthracene
(DMBA). Rad18-deficient fibroblasts aberrantly accu-
mulated DNA damage markers after DMBA treatment.
Moreover, in vivo DMBA treatment led to increased
incidence of B cell malignancy in Rad18−/− mice.
These results identify novel hematopoietic functions
for Rad18 and provide the first demonstration that
Rad18 confers DNA damage tolerance and tumor-
suppression in a physiological setting.
INTRODUCTION
Cells are frequently subject to DNA damage from environ-
mental, intrinsic and therapeutic sources. Failure to toler-
ate and accurately repair DNA damage can lead to loss of
cell viability or genome instability, an enabling characteris-
tic of cancer cells (1). The E3 ubiquitin ligase RAD18 plays
key roles in Trans-Lesion Synthesis (TLS), a DNA damage
tolerance mechanism that allows cells to replicate genomes
harboring bulky DNA lesions including polycyclic aryl hy-
drocarbon (PAH) adducts (2). In response toDNAdamage,
RAD18 redistributes to stalled DNA replication forks (3,4)
and mono-ubiquitinates the DNA polymerase processivity
factor PCNA (5). DNA damage-tolerant ‘Y-family’ TLS
DNA polymerases possess ubiquitin-binding domains and
associate preferentially withmono-ubiquitinated PCNA (6)
to promote replicative bypass of DNA lesions and DNA
damage tolerance (7). However, TLS polymerases are inher-
ently error-prone when compared to replicative DNA poly-
merases and can generate mutations. Thus, RAD18 and its
effector TLS polymerases can confer viability, but also have
the potential to compromise genome stability (7). Indeed
Rad18-deficient cells are genotoxin-sensitive and hypomu-
tagenic for bypass of various DNA lesions, including PAH
(8,9). The RAD18-mediated TLS pathway has been stud-
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ied extensively in cultured cancer cell lines. However, it is
not known if RAD18 contributes DNA damage tolerance
in vivo or whether mutagenic RAD18-mediated TLS influ-
ences carcinogenesis in a physiological setting.
In addition to its role in TLS, RAD18 is implicated as
an apical component of the Fanconi Anemia (FA) DNA
repair pathway in cultured cancer cells (10–13). FA is
a bone marrow failure (BMF) syndrome that is associ-
ated with developmental defects, reduced fertility (14,15)
and cancer-propensity, in particular Acute Myelogenous
Leukemia (16,17). FA can result from congenital defects
in any one of the 18 known FANC genes whose encoded
proteins (termed ‘FANCs’ A-T) participate in common
pathway of DNA replication-coupled inter-strand crosslink
(ICL) repair. FA patient cells are hypersensitive to ICL-
inducing agents such asMitomycin C (MMC).When DNA
replication forks encounter ICL, a multi-subunit FA ‘core
complex’ mono-ubiquitinates FANCD2 and FANCI (18).
Mono-ubiquitinated FANCD2-FANCI is the effector of
the FA pathway and directs ICL repair, most likely promot-
ing endolytic processing of crosslinked DNA (19). The FA
pathway is also activated in response to many genotoxins
that induce replication fork stalling (10), although FANC-
deficiencies generally result in more modest sensitivity to
DNA lesions other than ICL (20). ICL are complex lesions
and ICL repair requires coordination of the FA pathway
with three other DNA repair processes including TLS, ho-
mologous recombination (HR) and nucleotide excision re-
pair (NER) (17,18).
All hematopoietic lineages are compromised in FA indi-
viduals, indicative of hematopoietic stem cell (HSC) dys-
function (16). Indeed, most FA patients have significantly
lower numbers of CD34+ cells, a population that is en-
riched for HSCs and can reconstitute all other hematopoi-
etic lineages upon transplantation. Hematopoietic stem and
progenitor cells (HSPC) attrition in FA patients is due to
failure to tolerate endogenously-arising DNA lesions (21).
Aldehydes, generated via respiratory metabolism, represent
a major source of lethal ICL in HSPC from FA individuals
(22,23). Unrepaired DNA damage in FA individuals leads
to loss of HSPC viability via p53-mediated apoptosis (24).
Failure to repair DNA damage appropriately can cause
mutations and genome rearrangements that drive cancer.
Therefore, the reduced DNA repair capacity of HSC and
the ensuing aberrant processing ofDNAdamage contribute
to the hematological malignancy commonly observed in
FA.
A relationship between TLS and FA has been suspected
for many years for several reasons: (i) TLS is a necessary
step in ICL repair. (ii) FA patient-derived and other FANC-
defective cells are hypomutable, indicating reduced activ-
ity of the TLS pathway when the FA pathway is compro-
mised (25–27). (iii) FANCC is epistatic with the Y-family
TLS polymerase REV1 for cisplatin sensitivity in vertebrate
cells (27). (iv) The de-ubiquitinating (DUB) enzyme USP1
removes the ubiquitin moiety from mono-ubiquitinated
forms of PCNA and FANCD2, thereby coordinating activ-
ities of both the TLS and FA pathways (28,29).
Several lines of recent evidence directly implicate RAD18
in FA pathway activation (10–13) and ICL repair (30):
in cultured cells, RAD18-deficiency leads to reduced
FANCD2 mono-ubiquitination in response to ICL (11),
bulky adducts (10) and Topoisomerase I inhibitors (12).
In response to bulky DNA lesions and ICL, RAD18-
dependent FANCD2 mono-ubiquitination depends upon
PCNAmono-ubiquitination and TLS polymerases (10,13).
In contrast, RAD18-mediated FANCD2 ubiquitination
arising from DNA Topoisomerase I inhibition, is TLS-
independent (12). RAD18 also mediates association of the
SMC5/6 complex with ubiquitylated proteins in the vicin-
ity of DNA crosslinks, thereby promoting the HR phase of
ICL repair in cancer cell lines (30). Combined depletion of
RAD18 andFANCD2does not have additive effects on sen-
sitivity to ICL (11) or Topoisomerase I inhibition (12), in-
dicating an epistatic relationship between RAD18 and the
FA pathway.
Published studies showing RAD18-dependent FANCD2
activation in cultured cells raise the interesting possibil-
ity that RAD18 is also important for physiological FA
pathway functions in hematopoietic genome maintenance,
and implicate RAD18 as a potential FANC gene (although
no RAD18-deficient FA patients have yet been reported).
However, it cannot be assumed that hematopoietic pro-
genitor cells in a physiological setting necessarily rely on
the same genome maintenance mechanisms that confer
DNA damage tolerance in cultured cell lines. Moreover,
cultured cell lines (which are mostly cancer-derived) typ-
ically express aberrantly high RAD18 levels when com-
pared with untransformed and primary cells, raising the
possibility of neomorphic RAD18 roles in FA pathway ac-
tivation in (RAD18-overexpressing) cancer cells. Accord-
ingly, the work described here was undertaken to determine
the extent to which Rad18 confers hematopoietic genome
maintenance in vivo. Using Rad18 mutant mice, we have
asked whether Rad18-deficiency recapitulates the hallmark
hematopoietic defects that arise from FA pathway dys-
function and impaired ICL repair. Additionally, we have
tested physiological roles of Rad18 in DNA damage tol-
erance, characterizing the effects of Rad18-deficiency on
hematopoiesis basally and following exposure to various
myelosuppressive genotoxins. Our results define novel roles
for Rad18 in hematopoietic DNA damage tolerance and
suppression of B cell malignancy. Unexpectedly, we also
show that the FA pathway is intact in Rad18−/− cells and
that Rad18 mutant mice are phenotypically distinct from
Fanc mice, indicating that the Rad18 and FA pathways are
separable in vivo.
MATERIALS AND METHODS
Human CD34+ cell isolation
De-identified, donor leukapheresis discard products and
de-identified cord blood samples were obtained with Duke
University Medical Center IRB approval. Leukapheresis
products were thawed with DNase-containing media before
positive selection using Miltenyi CD34+ beads. Freshly ac-
quired Carolinas Cord Blood Bank cells subjected to an
EasySepTM Human Cord Blood CD34 Positive Selection
Kit. CD34+ cell frequency within the CD34-enriched and
-depleted fractions was assessed by flow cytometry.
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Mice and breeding
Mice were maintained with standard diet in a pathogen-free
environment. Rad18−/− mice in a C57BL/6J background
were described previously (31). ‘Knock-in’ mice expressing
HA-hRAD18 WT and HA-hRAD18-DC2 (mutant lack-
ing amino acids 402–445) from the endogenous Rad18 pro-
moter were generated as described (32).
Genotoxin administration
7,12-Dimethylbenz[a]anthracene (DMBA, ACROS
OrganicsTM) was dissolved in olive oil to [6.66 mg/ml].
Mice were orally-gavaged with DMBA solution (versus
olive oil control) to 50 mg/kg. MMC (Sigma) reconstituted
in phosphate buffered saline (PBS) was injected i.p. at 1
mg/kg. For H2O2 treatments, mice were injected i.v. with
freshly-diluted H2O2 (in PBS) for final in vivo concentration
of 200 M, as described (33).
Bone marrow transplantation
Donor BM cells were harvested from Rad18+/+ or
Rad18−/− (CD45.2) and B6.BoyJ (CD45.1 competitor)
mice in RPMI 1640 (GIBCO) containing 2% FBS, 10
unit/ml heparin, penicillin and streptomycin. BM cells
were centrifuged, washed and re-suspended in serum-free
medium. Recipient B6.BoyJ mice were lethally irradiated
(1000 cGy) 4 h before injection with 0.2 ml of 1 × 107/ml
cells containing a 1:1 mixture of CD45.2 donor and CD45.1
competitor cells. Recipient mice were fed acidified (pH =
2.6), antibiotic-containing water for 4 weeks and acidified
antibiotic-free water for the remainder of the experiment.
Blood samples were collected from recipient mice 8 and 16
weeks post-transplant. BM cells were harvested 16 weeks
post-transplant. CD45.1 and CD45.2 cell subsets were de-
termined by flow cytometry.
Clonogenic analysis of myeloid and B-lymphoid progenitors
BM cells were cultured in Methocult GF M3434 (gran-
ulocyte, macrophage–colony-forming units [CFU-GMs];
erythroid–burst-forming units [BFU-Es]; and granulocyte,
erythrocyte, macrophage, megakaryocyte–CFUs [CFU-
GEMMs]) at 5 × 104 cells/35 mm plate and MethoCult
M3630 (CFU–Pre-Bs; Stem Cell Technologies, Vancouver,
BC, Canada) at 2 × 105 cells/35 mm dish according to
the manufacturer’s instructions. Colonies were counted 7
(MethoCult M3630) and 10 days (Methocult GF M3434)
after plating.
Cells and culture
Mouse embryonic fibroblasts (MEF) were obtained from
day 13 embryos and cultured in Dulbecco’s modified
Eagle’s medium (DMEM) containing 10% fetal bovine
serum, streptomycin sulfate (100 g/ml) and penicillin (100
units/ml). MEF were trypsinized and re-plated at a density
of 1:3 after reaching 80% confluence. Swiss 3T3 cells were
cultured exactly as described for MEF.
Spermatocyte spreads and immunoflouresence
Spermatocyte spreads were prepared and stained as de-
scribed elsewhere (34,35). To visualize stained chromo-
somes, Z-stacks of each channel were taken on a Zeiss Ax-
ioImager M2 microscope, using the Axiovision software
package (Zeiss). SCP3 and H2Ax patterns were used to
stage spermatocytes, and intensity adjusted for presenta-
tion purposes. Primary antibodies (and dilutions) used for
immunoflouresence were: SCP3 (Abcam, 1:500), H2AX
(EMD Millipore, 1:1000), rabbit anti-mRad18 (described
by Tateishi et al. (36), 1:100), rabbit-anti-FANCD2 (Epit-
omics, 1:50); Secondary antibodies, donkey-anti-rabbit-
Alexa647 and donkey-anti-mouse-Alexa568 (Invitrogen)
were diluted 1:500. DNA was counterstained with DAPI.
Flow cytometry analysis
For cell cycle analyses, MEF were trypsinized, fixed and
propidium iodide (PI)-stained as described (8). PI-stained
cells were analyzed on an Accuri C6 flow cytometer (BD,
San Jose, CA, USA), and cell cycle profiles generated us-
ing FCS express 3 software (De Novo Software, Glendale,
CA, USA). For blood and BM (single-cell suspensions pre-
pared from single femurs), RBCs were eliminated using
ACK lysis buffer. To detect murine cell surface antigens, vi-
ability dye (Zombie AquaTM Fixable Viability Kit, BioLe-
gend) and anti-CD16/32 to block Fc receptors (TruStain
fcXTM, BioLegend) were used. Cells were stained using
predetermined optimal concentrations of antibodies for
30 min. Antibodies used included: anti-B220 (RA3–6B2),
anti-CD43 (1B11), anti-CD4 (GK1.5) and anti-CD127 (IL-
7R, A7R34), all from BioLegend, Inc. and; anti-Gr-1
(Ly-6G, RB6–85C), anti-CD3 (145–2C11), anti-Sca-1 (D7)
and anti-CD117 (c-Kit, 2B8), all from eBioscience, Inc.,
San Diego, CA, USA. To assess proliferation, intracellular
staining for the nuclear proliferation marker Ki-67 (clone
SolA15, eBioscience) was performed immediately following
cell surface staining according to the manufacturer (using a
FoxP3/Transcription Factor Buffer Set, eBioscience). Cells
were analyzed on a FACSCantoTM (BD Biosciences) and
FlowJo software (version X).
Isolation of LSK, lineage-negative and lineage-committed
cells from mouse bone marrow
Single-cell suspensions of total bone marrow cells were pre-
pared from the bilateral femurs of C57Bl/6 mice. Lineage-
committed cells were then removed with magnetic beads us-
ing a mouse Lineage Cell Depletion Kit (Miltenyi Biotec,
Inc.). Lineage-negative cells were subsequently stained with
antibodies against Sca-1 (D7) and CD117 (c-Kit, 2B8) to
identify the LSK population, with 7-AAD added to ex-
clude dead cells. Viable LSK cells and lineage-negative cells
depleted of the LSK subset were then each isolated us-
ing a MoFloTM XDP cell sorter (Beckman Coulter, Inc).
The LSK subset was verified to at least 94% pure as de-
termined by post-sort flow cytometry analysis. Cell ex-
tracts of LSK cells, LSK-depleted lineage-negative cells and
lineage-committed cells depleted of RBCs (using ACK ly-
sis buffer) were prepared and analyzed by SDS–PAGE with
immunoblotting as described below.
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SDS-PAGE and immunoblotting
Cell extracts were prepared and analyzed by SDS-PAGE
with immunoblotting as described previously (8). Pri-
mary antibodies were: p-ATM S1981 (SC-47739), -
actin (SC-130656), mouse monoclonal PCNA clone PC10
(SC-56), GAPDH (SC-32233, Santa Cruz Biotechnology
Inc.); Rad18 (A301–340A, Bethyl Laboratories Inc.; ATM
(GTX70104, Gene Tex); mouse monoclonal H2AX S139
(05–636, EMD Millipore); and FANCD2 (2986–1, Epito-
mics Inc.).
Statistics
Group comparisons of flow cytometry data and cell survival
results were analyzed by Student’s t-test. Tumor subtype
frequency comparison was analyzed using Chi square test.
The frequency of Fancd2 distribution to asynaptic chromo-
somes inmice from different genotypes was analyzed byChi
square test.
RESULTS
Expression of Rad18 and Fancd2 in hematopoietic progeni-
tors
We examined the relative expression levels of Rad18
and Fancd2 proteins in different subsets of hematopoi-
etic progenitor cells from wild-type mice. As expected,
Fancd2 was expressed highly in isolated (Lin-)/Sca-1+/c-
kit+ (LSK) cells, a population containing the most primi-
tive hematopoietic stem cells that possess self-renewal ca-
pacity and can give rise to all other lineages present in the
BM and circulating blood. Fancd2 was also expressed in
lineage-negative (Lin-) cells that do not yet express mark-
ers ofmoremature lineage-committed blood cells. However,
in lineage-committed (Lin+) cells Fancd2 was expressed at
only 5% of the levels present in LSK and Lin- cells (Figure
1A, lane 3 of Fancd2 blot). The expression profile of Fancd2
in different progenitor subsets is consistent with the estab-
lished roles of the FA pathway in genome maintenance of
primitive hematopoietic progenitors.
Similar to FANCD2, Rad18 was expressed in LSK cells,
but was expressed at greatly reduced levels (∼3%) in the
Lin− cells and was undetectable by immunoblotting in
Lin+ cells (Figure 1A, lanes 2 and 3 of Rad18 blot). For the
purpose of comparison, we examined expression of Chk1,
an S-phase checkpoint kinase that is typically activated co-
incident with Rad18 and the FA pathway in response to
replication fork stalling. Similar to FANCD2, Chk1 was ex-
pressed at high levels in LSK and Lin− populations, but not
in Lin+ cells. Therefore, Rad18 and Fancd2 are specifically
co-expressed in LSK cells, but not in the Lin− population.
These expression profiles are potentially consistent with a
role for Rad18 in FA pathway activation in some mouse
hematopoietic progenitor subsets.
For the purpose of comparison with mouse LSK cells, we
also examined relative expression of Rad18 and FANCD2
in human HSC. In humans, CD34+ hematopoietic pro-
genitors are enriched in HSC and critically require the
FA pathway for their normal functions in vivo (24). Using
leukapheresis samples from G-CSF-treated healthy human
donors we isolated CD34+ cells and analyzed Rad18 and
FANCD2 levels by immunoblot. Purity of the CD34+ cells
was >90% (Figure 1B). Both Rad18 and FANCD2 were
highly expressed in CD34+ cells relative to the more dif-
ferentiated CD34− cells. Similar to leukapheresis-derived
samples, we detected expression of Rad18 (and FANCD2)
only in CD34+ cells from fresh human umbilical cord blood
(Figure 1C). Moreover, expression of Rad18 and FANCD2
was insensitive to in vitro culture with G-CSF. The high-
level co-expression of Rad18 in CD34+ cells is consistent
with a role for Rad18 in primitive hematopoietic stem cell
function and hematopoiesis in mice and humans.
Rad18-FA signaling and ICL-tolerance in Rad18−/− cells
Since cells from FA patients are hypersensitive to ICL-
inducing agents such as MMC, we tested the role of Rad18
in FA pathway activation and ICL tolerance in primary
mouse cells. FA cells undergo an aberrant and persistent
G2 arrest in response to MMC treatment, owing to inap-
propriate processing of ICL to DNA breaks (37,38). As
shown in Figure 1D, a 48 h treatment with 15 nM MMC
led to a 2-fold increase in the G2/M population of pri-
mary Rad18+/+ MEF but increased the G2/M popula-
tion of Rad18−/− cells by 3.6-fold (Figure 1D). The aber-
rant MMC-induced G2/M arrest of Rad18-null cells was
also evident when we used independent isogenic cultures of
Rad18+/+ andRad18−/− littermateMEFderived froma dif-
ferent pregnant female (Supplementary Figure S1). When
comparing the two independent sets of isogenic MEF, in
Rad18+/+ cells 15 nMMMC induced a 2.05 ± 0.05-fold in-
crease in theG2/Mpopulation, whereas inRad18−/− MEF,
15 nM MMC induced a 3.9 ± 0.3-fold increase in G2/M
content, a difference between genotypes that is statistically
significant by conventional criteria (P = 0.026).
The aberrant G2/M arrest of Rad18−/− MEF recapitu-
lates a hallmark ICL-tolerance defect of FA cells. Surpris-
ingly, however, the MMC-induced G2 arrest of Rad18−/-
MEF was associated with a 2.0-fold increase in ubiquiti-
nation and chromatin-association of Fancd2 that was iden-
tical to the fold-increase in Fancd2 chromatin binding in
WT cells (Figure 1E). Therefore, Rad18 is dispensable for
ICL-induced FA pathway activation in primary cells. Inter-
estingly, basal levels of Fancd2 on chromatin were 2.4-fold
higher in Rad18−/− cells when compared with WT MEF.
The increased chromatin binding of Fancd2 in Rad18−/−
cells likely reflects compensatory activation of the FA path-
way to enable tolerance of DNA replication stress tolerance
when TLS is absent. Rad18−/− MEF were MMC-sensitive
when compared with Rad18+/+ MEF, as shown by clono-
genic survival assays (Figure 1F and Supplementary Figure
S1).
The MMC-sensitivities of Rad18−/− MEF fully reca-
pitulate the expected MMC-tolerance defects of Fanca−/−
fibroblasts (Supplementary Figure S2) as revealed under
identical experimental conditions. As expected, Fanca−/−
cells lacked the slowly-migrating mono-ubiquitinated
species of Fancd2, although Fancd2 mono-ubiquitination
is intact in Rad18−/− MEF (Figure 1E). We conclude
that Rad18 is not an obligate upstream component of
the FA pathway and contributes to MMC tolerance in-
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Figure 1. RAD18 is expressed in HSPC and confers ICL-resistance in primary MEF. (A) LSK cells, Lin− cells and Lin+ populations were isolated from
total BM cells of Rad18+/+ mice as described under Materials and Methods. Protein extracts from the resulting populations were resolved by SDS-PAGE
and analyzed by immunoblotting with antibodies against Fancd2, Rad18, Chk1 and GAPDH. (B) CD34+ and CD34− cells were isolated from GCSF-
provoked human leukapheresis product. Purity of the CD34+ population was verified by anti-CD34-staining and flow cytometry (left panel). Extracts from
the purified cells were resolved by SDS-PAGE and analyzed by immunoblotting with antibodies against Rad18, Fancd2 and -Actin (loading control).
(C) CD34+ and CD34− cells were isolated from human umbilical cord blood. Purity of the CD34+ population was verified by anti-CD34-staining and
flow cytometry (left panel). CD34+ and CD34− cells were resuspended in RPMI medium and cultured for 18 h in the presence or absence of G-CSF
(Neupogen, 500 ng/ml). The resulting cells were washed with PBS and lysed. Cell extracts were resolved by SDS-PAGE and analyzed by immunoblotting
with antibodies against Rad18, Fancd2 and -Actin (loading control). (D) Replicate cultures of exponentially-growingRad18+/+ andRad18−/- MEFwere
incubated for 48 hr with MMC (30 nM) or were left untreated for controls. Nuclei from the resulting cells were stained with PI and DNA contents of
all samples were analyzed by flow cytometry. (E) Replicate cultures of exponentially-growing Rad18+/+ and Rad18−/- MEF were incubated for 2 h with
MMC (60 nM) or were left untreated for controls. Chromatin fractions obtained from the resulting cultures were resolved by SDS-PAGE and analyzed by
immunoblotting with antibodies against Fancd2, Rad18, PCNA and Actin. (F) Replicate cultures of exponentially-growing Rad18+/+ and Rad18−/- MEF
were incubated with various doses of MMC for 2 days and analyzed for clonogenic survival. On the survival curves, each data point represents the mean of
three replicate determinations and error bars represent the range. For each dose of MMC, we performed unpaired Student’s t-test between between groups.
For cells that received 2, 5 or 10 nM MMC, the P-values were 0.0055, 0.0002 and 0.0006, respectively, indicating significant differences between MMC-
tolerance of Rad18+/+ and Rad18−/− cells. (G) Replicate cultures of exponentially-growing MEF from hRAD18 (WT) and hRAD18 DC2 knock-in mice
were incubated with various doses of MMC for 2 days and analyzed for clonogenic survival (left panel). On the survival curves, each data point represents
the mean of three replicate determinations, and error bars represent the range. Statistical significance was determined as described in (F) above. For cells
that received 5, 10 or 20 nM MMC, the P-values were 0.49, 0.67 and 0.6, respectively, indicating no significant differences between MMC-tolerance of
hRAD18 (WT) and hRAD18 DC2MEF. Whole cell extracts from hRAD18 (WT) and hRAD18 DC2MEF were resolved by SDS-PAGE and analyzed by
immunoblotting with anti-Rad18 antibodies to verify equivalent expression of the wild-type and mutant hRAD18 proteins (right panel).
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dependently of its previously described proximal role in
mediating Fancd2 ubiquitination in cancer cells (10,30). To
determine whether Rad18 and the FA pathway function
in a common pathway of ICL-tolerance in primary mouse
cells (as previously reported using cancer cell lines) we
determined the effects of individual and combined Rad18
and Fanca-deficiencies on MMC-sensitivity. Using Rad18-
directed siRNA we achieved >95% depletion of Rad18 in
both Fanca+/+ and Fanca−/− cells (Supplementary Figure
S2B). Rad18-depletion had no effect on Fancd2 levels or
monoubiquitination (as expected), and did not further
sensitize the Fanca mutant MEF to MMC. Because partial
Rad18-depletion did not sensitize Fanca-mutant MEF to
MMC, Rad18 probably functions downstream of the FA
pathway. However, Rad18-knockdown did not sensitize
Fanca+/+ MEF to MMC, whereas Rad18−/− MEF were
MMC-sensitive (see Figure 1F and Supplementary Figure
S1). We conclude therefore that the low residual levels of
Rad18 (<5%) present in siRad18-transfected MEF are
sufficient to support normal MMC-tolerance.
In human cancer cells, Rad18 facilitates association of the
SMC5/6 complex with ubiquitylated proteins in the vicin-
ity of DNA crosslinks to promote DNA repair (30). To de-
termine the contribution of Rad18-Smc5/6 interactions to
MMC-tolerance, we prepared MEF from ‘knock-in’ mice
expressing physiological levels of wild-type hRAD18 or
the hRAD18 ‘DC2’ mutant (which lacks the SMC5/6-
interacting domain) from the endogenous Rad18 promoter.
As shown in Figure 1F, hRAD18 (WT) and hRAD18
DC2 MEF expressed similar levels of RAD18 protein and
showed normal MMC tolerance. As expected, ubiquitina-
tion of Fancd2 was not compromised in hRAD18 DC2
MEF when compared with hRAD18WT cells (Supplemen-
tary Figure S3). Taken together, results of Figure 1C–F
show that Rad18 is dispensable for FA pathway activation
in response to MMC, and confers ICL-tolerance indepen-
dently of its association with Smc5/6 in primary MEF.
Rad18-deficiency does not recapitulate basal hematopoietic
defects of Fanc mutant mice
The defective ICL tolerance of Fanc mutant mice typically
leads to decreased HSC numbers (15,39,40). We quantified
hematopoietic cells in peripheral blood and bone marrow
fromWT andRad18−/- mice. As shown in Figure 2A and B,
there was no statistically-significant difference in the num-
bers of total cells, Lin−, LSK or CLP populations in the
BM when comparing Rad18+/+ and Rad18−/− mice. In the
peripheral blood, there were modest but significant (P <
0.05) increases in T and B cells in Rad18−/− mice (1.5-fold
for T cells, 1.6-fold for B cells), but these changes were in-
dependent of progenitor cell numbers in the BM. Taken to-
gether, these results show that there is no basal hematopoi-
etic defect in Rad18-deficient mice.
Fanc-deficient HSPC have reduced capacity for comple-
mentation of hematopoiesis in irradiated recipient animals
which lack a functional immune system (39,41–43). There-
fore, bone marrow transplant (BMT) experiments were per-
formed to compare the engraftment potential of donor
Rad18+/+ and Rad18−/− HSC. BM cells from Rad18+/+
or Rad18−/- mice (expressing CD45.2) were mixed with
CD45.1competitor BM cells and transplanted into lethally-
irradiated hosts (see Figure 2C). After 8 weeks, donor
chimerism was determined by flow cytometric staining
of nucleated peripheral blood cells with anti-Cd45.1 and
anti-CD45.2 in the recipient mice (41). After 16 weeks,
donor chimerism was determined for both nucleated pe-
ripheral blood cells and BM progenitors. As shown in Fig-
ure 2D, Rad18−/− donor BM efficiently reconstituted all
hematopoietic cell subsets analyzed in lethally-irradiated re-
cipient mice. No significant differences in reconstitution ef-
ficiency were observed between WT and Rad18–/− donor
BM.
Next we asked whether FA-like phenotypes of Rad18−/−
mice could be revealed by genotoxin challenge. In the
C57BL6 background a single dose of 1 mg/kg MMC kills
Fancc−/− (but not WT) mice in within 10 days (40). In con-
trast with Fancc mutants, Rad18−/− (and Rad18+/+) mice
tolerated 1 mg/kg MMC and showed no adverse health
effects (body weight, grooming, posture and activity) for
at least 3 weeks (not shown). Therefore, Rad18−/− mice
do not phenocopy the sensitivity of Fanc mice to 1 mg/kg
of MMC. In other experiments we treated Rad18+/+ and
Rad18−/− micewith a range of higherMMCconcentrations
including 1, 2, 4 and 8 mg/kg. AnMMC concentration of 8
mg/kg killed bothRad18+/+ andRad18−/-mice after 9 days.
There was no MMC concentration or length of treatment
that selectively killed Rad18−/− mice but not WT animals,
consistent with our overall conclusion that Rad18 is not a
major contributor to the FA pathway and ICL resistance in
vivo.
We also determined the effects of MMC on hematopoi-
etic cells in the peripheral blood and bonemarrow including
the repopulating lineage negative LSK and Lin-/Sca-1+/c-
kit-IL-7R+ common lymphoid progenitor (CLP) popula-
tions. Remarkably, Rad18−/− mice had no detectable im-
pairment in hematopoietic cell development or in periph-
eral immune cell subsets relative to WT control mice (Fig-
ure 3A). Hematopoietic cells in Fanca−/− mice are sensitive
to H2O2-induced genotoxicity (33). However, as shown in
Figure 3B, Rad18-deficiency did not lead to defective H2O2
tolerance in LSK cells or other lineages. We conclude that
while Rad18 may sometimes contribute to FA pathway in
cultured cells, Rad18-deficiency does not compromise nor-
mal hematopoiesis or recapitulate hallmark hematopoietic
genotoxin-sensitivities of Fanc-deficient mice.
Rad18 confers hematopoietic PAH tolerance
Next, we tested whether Rad18 contributes to maintenance
of normal hematopoietic function following in vivo expo-
sure to other classes of genotoxins. DMBA, a PAH, tar-
gets hematopoietic progenitors, leading to anemia in the
short term (44–47) and hematological malignancy in the
long term (48–50). The genome maintenance pathways that
prevent hematopoietic dysfunction following PAH expo-
sure have not been investigated.
As shown in Figure 4A, Rad18-depleted 3T3 cells aber-
rantly accumulated the DSB markers ATM (pS1981) and
H2AX following DMBA treatment, showing that Rad18
confers DMBA-tolerance, at least in cultured cells. To test
a potential role for Rad18 in protecting hematopoietic pro-
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Figure 2. Rad18 deficiency does not impair hematopoiesis in otherwise normalmice. (A andB) Blood and bonemarrow cells isolated from un-manipulated
Rad18−/− mice and their WT littermates were stained for cell surface markers and assessed for populations of interest by flow cytometry. Each data point
represents the cell number results from an individual mouse, with the mean indicated for each group (see Supplementary Figure S1 for bone marrow
progenitor cell gating strategy). (C) Experimental scheme used to determine effects of Rad18-deficiency on bone marrow engraftment following HSCT.
Lethally-irradiated WT B6.SJL recipient mice (CD45.1 allele) were reconstituted with donor bone marrow from Rad18−/− mice or their WT littermates
(each harboring the CD45.2 allele). Prior to transfer, donor bone marrow from each mouse was mixed with competitor bone marrow from normal B6.SJL
mice at a 1:1 ratio. 16 weeks following transfer, blood and bone marrow of recipient mice were assessed for the frequency of donor CD45.2 cells in various
cell subsets by flow cytometry. (D) Blood and bone marrow were obtained fromHSCT recipient mice and assessed for the frequency of donor CD45.2 cells
in various cell subsets by flow cytometry, defined by the percentage of total CD45.1+ and CD45.2+ donor cells (see Supplementary Figures S4 and S5 for
bone marrow progenitor cell gating strategy). Statistical analysis was performed using an unpaired, two-tailed Student’s t-test. Mean values significantly
different between genotypes are indicated (*P < 0.05).
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Figure 3. Rad18-deficiency does not recapitulate hematopoietic genotoxin-sensitivities of Fanc-deficient mice.Rad18−/− mice or theirWT littermates were
treated with a single dose ofMMC (A) or H2O2 (B) as described in ‘Materials andMethods’. Five days followingMMC treatment and 24 h followingH2O2
treatment, mice were euthanized and their bone marrows assessed for cell populations of interest by flow cytometry. Statistical analysis was performed
using an unpaired, two-tailed Student’s t-test. No cell subset comparisons between genotypes or different treatment groups of the same genotype reached
statistical significance.
genitors from PAH-induced DNA damage in vivo we used
an established experimental regimen (Figure 4B) in which
short-term DMBA treatment induces myelosuppression
and chronic repeat DMBA treatments lead to hematopoi-
etic malignancy (44,45,47,51). As shown in Figure 4C, the
numbers of LSK cells in the BM of Rad18-/- mice were
reduced to 25% (P < 0.01) of the population present in
WT mice after a single DMBA challenge. The LSK pop-
ulation was specifically sensitive to depletion by a single
DMBAdose, while other cell populations (including B cells,
T cells, CLP and Lin- cells) were largely unaffected (Figure
4C). Therefore, the repopulating LSK subset is likely to be
the most sensitive to short-term DNA damage, with Rad18
playing a clear role in LSKmaintenance under these condi-
tions.
We asked whether the Rad18-Smc5/6 interactions that
contribute to MMC-tolerance in cancer cells (30) are in-
volved in DMBA-tolerance in vivo. Therefore, we com-
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Figure 4. DMBA-sensitivity of Rad18-depleted Swiss 3T3 fibroblasts and hematopoietic progenitors. (A) Replicate cultures of Swiss 3T3 cells were trans-
fected with siRNA against Rad18 (siRad18) or with non-targeting control oligonucleotides (siCon). The resulting cultures were treated with 1 MDMBA
for 24 h. Chromatin extracts were prepared from the resulting cells and subject to SDS-PAGE and immunoblotting with the indicated antibodies. (B)
Summary of DMBA treatment regimen used in this study to determine DNA damage-sensitivities and carcinogenesis in Rad18+/+ and Rad18−/− mice.
(C)Rad18+/+ andRad18−/− mice were treated with a single dose of DMBA (50mg/kg). Forty eight hours later bonemarrow cells from the DMBA-treated
mice were stained with antibodies against appropriate cell surface markers and assessed for various hematopoietic cell subsets using flow cytometry. Sta-
tistical analysis was performed using an unpaired, two-tailed Student’s t-test. Mean values significantly different between genotypes are indicated (*P <
0.05; **P < 0.01).
pared the MMC-sensitivity of hematopoietic progenitors
in knock-in mice expressing WT and DC2 (SMC5/6-
interaction-deficient) hRAD18 alleles. As shown in Supple-
mentary Figure S6, there were no significant differences in
numbers of total BM cells, LSK cells or Lin− cells basally
or afterDMBA-treatmentwhen comparing hRAD18 (WT)
and hRAD18 DC2 mice. We conclude that the Rad18-
Smc5/6 interaction that confers MMC-tolerance in cancer
cells (30) does not contribute significantly to maintenance
of hematopoietic progenitors basally or after DMBA treat-
ment in vivo.
Based on the sensitivity of LSK cells to a single dose
of DMBA, we hypothesized that repeat DMBA challenge
would prematurely exhaust HSPC pools in Rad18-deficient
animals. Therefore, Rad18+/+ and Rad18−/− mice were ad-
ministered three bi-weekly doses of DMBA or were left un-
treated for controls. The in vivo engraftment potential of
HSPC from the DMBA-treated animals was determined
using BMT (Figure 5A). Sixteen weeks post-transplant,
analysis of donor chimerism of recipient mice showed spe-
cific reductions in numerous cell populations derived from
DMBA-treated Rad18−/− donor mice (CD45.2+) in BM
(Figure 5B) and blood (Figure 5C). For example in the BM,
numbers of Rad18+/+ progenitor-derived mature B-cells, T-
cells and LSK cells were modestly affected (27% decrease
for mature B cells, P < 0.05; 30% decrease for T-cells, P <
0.05) or unaffected (LSK cells, no significant difference) by
prior DMBA treatment of the donor mice. However, num-
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Figure 5. Impaired reconstitution of progenitor and hematopoietic cell populations by Rad18−/− HSC from DMBA-treated mice. (A) Experimental
design for testing effects of repeat DMBA treatments on engraftment potential of Rad18+/+ and Rad18−/− HSC. (B and C) 8 week-old male Rad18+/+
andRad18−/− littermatemicewere treatedwithDMBAby oral gavage bi-weekly. Bonemarrow cells were harvested 7 days after the thirdDMBA treatment.
Lethally-irradiated WT B6.SJL recipient mice (CD45.1allele) were reconstituted with donor bone marrow from either control or 3X bi-weekly DMBA-
treated Rad18−/− mice or their WT littermates (each harboring the CD45.2 allele). Prior to transfer, donor bone marrow from each mouse was mixed
with competitor bone marrow from normal B6.SJL mice at a 1:1 ratio. At 8 wks (blood) and at 16 wks (blood and bone marrow) following transfer, the
frequency of CD45.2 cells in various cell subsets was assessed by flow cytometry (see Supplementary Figure S1 for bone marrow progenitor cell gating
strategy). Statistical analysis was performed using an unpaired, two-tailed Student’s t-test. Mean values significantly different between genotypes are
indicated (*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001). (D) Rad18+/+ and Rad18−/− littermate mice were treated with DMBA by oral gavage
bi-weekly as described for the BM transplant experiment above. Bone marrow cells were harvested 7 days after the third DMBA treatment and cultured
in Methocult GFM3434 medium (which supports growth of granulocyte, macrophage–colony-forming units [CFU-GMs]; erythroid–burst-forming units
[BFU-Es]; and granulocyte, erythrocyte, macrophage, megakaryocyte–CFUs [CFU-GEMMs]) or MethoCult M3630 (which allows growth of CFU–Pre-
Bs) as described under ‘Materials andMethods’. Statistical analysis was performed using an unpaired, two-tailed Student’s t-test. Mean values significantly
different between genotypes are indicated (*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001).
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bers of mature B-cells T cells and LSK cells derived from
transplanted Rad18−/− progenitors were reduced by 75%
(P < 0.0001), 74% (P < 0.0001) and 88% (P < 0.001), re-
spectively, when the donor mice were DMBA-treated (Fig-
ure 5B). Similar results were obtained when we analyzed pe-
ripheral blood. For example, 8 weeks following transplant,
numbers ofRad18+/+-progenitor-derived B and T cells were
only reduced by 34% (P < 0.01) and 44% (P < 0.05) when
donor mice received DMBA. However, numbers of B and
T cells derived from Rad18−/− progenitors were reduced by
82% (P< 0.0001) and 79% (P< 0.001)%, respectively, when
the donor mice were administered DMBA (Figure 5C).
We also determined the effects of repeat DMBA treat-
ments on in vitro differentiation and proliferative poten-
tial of hematopoietic progenitors using colony-forming as-
says. In BM from DMBA-treated Rad18−/- mice there was
a 51% decrease in the number of pro-B progenitors (P =
0.035) and a 53% decrease in the number of combined
erythroid (BFU-E), granulocyte-macrophage (CFU-GM,
CFU-M, CFU-G) and multi-potential granulocyte, ery-
throid, macrophage, megakaryocyte (CFU-GEMM) pro-
genitors (P = 0.005) when compared with Rad18+/+ mice
(Figure 5D). In mice that did not receive DMBA, there was
no significant difference between Rad18+/+ and Rad18−/−
progenitors. Therefore, BM progenitors from DMBA-
treated Rad18−/− mice showed reduced in vitro colony
formation activity when compared with progenitors from
Rad18+/+ littermates (Figure 5D). We conclude that Rad18
is important for hematopoietic progenitors to tolerate long-
term PAH genotoxicity.
Effect of Rad18 on PAH-induced hematological malignancy
Reduced DNA damage tolerance of hematopoietic progen-
itors in BMF syndromes such as FA is associated with ge-
nomic instability and increased incidence of hematological
malignancy (16,17). Therefore, we determined the effect of
Rad18-deficiency on the onset of DMBA-induced hemato-
logical malignancies in Rad18+/+ (n = 26) and Rad18−/−
(n = 23) mice. Survival rates were indistinguishable be-
tween genotypes (Figure 6A). However, post-mortem anal-
ysis showed a 1.56-fold increase in the incidence of hema-
tological malignancies in Rad18−/− mice compared with
Rad18+/+ animals (P= 0.05). Although the difference in in-
cidence of hematological malignancies between genotypes
is not significant under the 5% significance level, it is sig-
nificant under the 10% significance level. Based on the cur-
rent data, we can say, with high confidence, that the differ-
ence between the proportions in theRad18+/+ group and the
RAD18−/− group is around 0.50–0.78 = −0.28. For exam-
ple, with 95% confidence, it is in the interval (−0.61, 0.04),
and with 90% confidence it is in the interval (−0.56,−0.04).
We cannot state with certainty in which direction the P-
value will go if sample size is increased, simply because of
random variation. However, based on the current data, if
the sample size is increased, it is likely that the difference in
proportions will be <0 (the Rad18+/+ group has a smaller
proportion) and the P-value will be <0.05.
Staining with appropriate antibodies was used to clas-
sify the DMBA-induced hematological malignancies (Fig-
ure 6B and Table 1). Interestingly, anti-B220 staining of tu-
Figure 6. Effects of repeat DMBA treatment on survival and malig-
nancy in Rad18+/+ and Rad18−/− mice. (A) Kaplan–Meier plots show-
ing survival rates of Rad18+/+ and Rad18−/− mice after repeat treatment
withDMBA. (B) Representative DMBA-induced tumors inRad18+/+ and
Rad18−/− mice: (a) Wright–Geimsa stained cytospin preparation of a nor-
mal bone marrow flush from a Rad18+/+ mouse (WT7) (original objec-
tive magnification 60x) showing maturation of the expected hematopoi-
etic elements including granulocytes, erythroids and megakaryocytes. (b)
Wright–Geimsa stained cytospin preparation of a bone marrow flush from
Rad18−/− mouse (KO9) mice. The expected heterogeneity seen in normal
bone marrow (evident in panel (a) is absent. The marrow cells are replaced
by a monotonous proliferation of discohesive, large, abnormal lymphoid
cells characterized by irregular nuclear contours and scant basophilic cyto-
plasm. (c) Hematoxylin and eosin (H&E) stained sections of liver showing
dense infiltrates of large abnormal lymphoid cells (original objective mag-
nification 20x). (d–g) B cell and T cell tumors are morphologically indis-
tinguishable. However, immunohistochemical staining identifies B cell tu-
mors (B220-positive/CD3-negative, shown in panels (d) and (e)) and T cell
tumors (CD3-positive/B220-negative, shown in panels (f) and (g)) (brown
chromogen is considered positive with blue counterstain for contrast. orig-
inal objective magnification 40x). (h) Skin lesions from a Rad18−/- mouse
demonstrating classic features of basal cell carcinoma with nodular collec-
tions of hyperchromatic basaloid cells extending from the epidermal sur-
face as indicated by the arrows (original objective magnification 20x).
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Figure 7. Rad18-dependency of FA pathway activation in meiotic cells.
(A) Spermatocyte spreads from Rad18+/+ mice were stained with the
indicated antibodies and analyzed by immunofluorescence confocal mi-
croscopy. The image shows co-localization of Rad18 (white) with H2AX
(Green) in pachytene spermatocytes from wild-type mice. The synaptone-
mal complex component SCP3 is shown in Red. Arrowheads indicate po-
sitions of the XY chromosomes. (B) Spermatocyte spreads fromRad18+/+
and Rad18−/- mice were stained with the indicated antibodies and ana-
lyzed by immunofluorescence confocal microscopy. In each of three sepa-
rate experiments >50 similarly staged meiotic spreads were obtained for
each genotype and scored for co-localization of Fancd2 or Fanci with
H2AX. The image shows representative spreads in which there is co-
localization of Fancd2 (red) with H2AX (blue) in pachytene spermato-
cytes from Rad18+/+ but not Rad18−/- mice. The synaptonemal complex
component SCP3 is shown in green. In a Chi square test, the differences in
Fancd2 distribution between genotypes were highly significant (P-value =
2 × 10−14).
mor sections revealed a 10-fold increase in the number of
B cell-positive malignancies inRad18−/− mice compared to
Rad18+/+ (P = 0.007). There was no statistically significant
difference in the incidence of T cell-positive malignancies
between genotypes.
Rad18-dependent FA pathway activation in germ cells
In addition to its critical roles in ICL repair, the FA path-
way mediates DSB processing during normal meiosis. Re-
distribution of Fancd2 to asynaptic (unpaired) chromo-
somes in meiotic spermatocytes is a hallmark of FA path-
way activation in vivo (52). Therefore, we investigated the
Rad18-dependency of DSB-induced FA pathway activation
in germ cells. Similar to Fancd2,Rad18was localized to asy-
naptic meiotic chromosomes, which are readily detectable
with intense H2AX staining (Figure 7A). As expected,
Fancd2 co-localized with H2AX in 95% of the spermato-
cytes from Rad18+/+ mice (Figure 7B). However, appropri-
ate redistribution of Fancd2 to asynaptic meiotic chromo-
somes was reduced to 40% inRad18−/- mice (Figure 7B, up-
per right panel). Based on Chi square test the difference in
Fancd2 localization between genotypes is highly significant
(P = 4 × 10−16). Therefore, in contrast with hematopoi-
etic cells (in which Rad18 and Fancd2 are not always co-
expressed and Rad18 and FA pathways are independent),
FA pathway activation by Spo11-induced DSB is Rad18-
dependent in germ cells in vivo.
DISCUSSION
Rad18 can promote FA pathway activation (10,12,13) and
ICL tolerance in cultured cancer cell lines (11). Specific ex-
pression of Rad18 in primary mouse LSK cells and hu-
man CD34+ cells (Figure 1A) further compelled the cur-
rent investigation of potential Rad18 roles in hematopoiesis
in a physiological setting. Unexpectedly, we found that un-
transformed Rad18−/− MEF maintain Fancd2 ubiquitina-
tion followingMMC treatment, yet display hallmarks of FA
cells (G2 arrest, MMC-sensitive survival). Why the Rad18-
dependency of MMC-induced Fancd2 ubiquitination dif-
fers between untransformed MEF and cancer cell lines re-
mains undetermined. Most cancer cells express very high
levels of Rad18 protein when compared with primary and
untransformed cells. It is possible that FA pathway activa-
tion is a ‘neomorphic’ function resulting from high Rad18
levels. Indeed, ectopic overexpression of Rad18 can pro-
mote Fancd2 ubiquitination in the absence of genotoxin
treatment (10). Thus although Rad18 may contribute to FA
pathway activation in some instances, we demonstrate here
that Rad18 is not essential forMMC-induced Fancd2 ubiq-
uitination (Figure 1D–F).
Nevertheless, because Rad18−/− MEF are MMC-
sensitive, Rad18 might have roles in ICL repair and
MMC-tolerance distal to Fancd2 ubiquitination, or
via scaffolding of the Smc5/6 complex to ubiquitylated
chromatin in the vicinity of damaged chromatin (30).
Using MEF from ‘knock-in’ mice expressing Smc5/6-
interaction-deficient RAD18 (Figure 1F), we reveal that
scaffolding does not contribute to RAD18-mediatedMMC
tolerance when RAD18 is present at physiological levels
in non-transformed cells. Fancd2 promotes a TLS step
during repair of ICL encountered by two converging
replication forks (19). Therefore, Rad18-mediated PCNA
mono-ubiquitination may facilitate the TLS phase of ICL
repair, perhaps explaining whyRad18-nullMEF areMMC-
sensitive despite efficiently mono-ubiquitinating Fancd2
in response to MMC. MMC does induce monoadducts
and the MMC-sensitivity of Rad18−/− cells could also be
explained by reduced TLS activity.
Based on MMC-sensitivity phenotypes of Rad18−/−
MEF we predicted, but did not find, that Rad18−/−
mice would exhibit the hallmark hematopoietic defects
of Fanc-deficient mice (Figure 2). Surprisingly, we found
that Rad18−/− mice tolerated MMC and displayed no
hematopoietic defects (such as reduced hematopoietic pro-
genitor number, reduced HSC proliferative and engraft-
ment potential, MMC-sensitivity or H2O2-sensitivity) (Fig-
ure 3). Therefore, Rad18 is unlikely to be a core component
of the FA pathway in hematopoietic cells. Thus, an impor-
tant conclusion of this study is that Rad18-dependencies
observed in cultured cancer cells are not necessarily repre-
sentative of Rad18 functions in vivo.
Our studies with a carcinogenic PAH (DMBA) (Figure
4), suggest an important in vivo role for Rad18 in tolerat-
ing certain classes of myelosuppressive agents that affect the
Y-family DNA polymerase Pol. Pol allows replication of
PAH-adducted genomes and prevents DSB and cell death
in cultured cells (8,53). Rad18 plays complex roles in the
DNA damage response by facilitating replication of dam-
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Table 1. Incidence of DMBA-induced hematological malignancies in Rad18+/+ and Rad18−/− mice
Hematologic malignancies (H&E) B Cell Lymphoma (B220 positive) T Cell Lymphoma (CD3 positive)
Rad18+/+ (n = 20) 10 (50%) 1 (5%) 6 (30%)
Rad18−/− (n = 23) 18 (78%) 11 (48%) 5 (22%)
P-value ns 0.007 ns
Figure 8. Hypothetical role of Rad18 in HSPC genome maintenance. In
wild-type HSPC, Rad18 supports replicative bypass of bulky DNA le-
sions, conferring DNA damage tolerance and maintaining hematopoiesis
in the face of genotoxin exposure. In genotoxin-exposedRad18−/− HSPC,
stalled replication forks cannot recover via TLS and collapse leading to
DNA DSB formation and attrition of hematopoietic progenitors. Error-
proneDSB repair via NHEJ has the potential to generate oncogenic events
such as translocations and gross chromosomal rearrangements that drive
hematological malignancy.
aged genomes and preventing DNA strand breaks at the ex-
pense of replication fidelity. Thus, genome maintenance via
Rad18 represents a ‘double-edged sword’ with the poten-
tial to avert genome-destabilizing DSB while causing muta-
tions.
Rad18 has been studied extensively in cell culture sys-
tems, yet whether the net effect of Rad18-mediated TLS
is tumor-suppressive or oncogenic in vivo has not previ-
ously been addressed. We show that Rad18-loss can cause
a tumor-propensity phenotype at least in the context of
B-cell malignancies (Table 1, Figure 6B). Most proba-
bly, DSB generated by DMBA-induced fork collapse in
Rad18-deficient hematopoietic progenitors initiate onco-
genic translocations that drive leukemia (Figure 8). If ele-
vated DSB sustained by early multipotent progenitors ac-
counts for the tumor propensity of Rad18−/− mice, it is
tempting to speculate that the increased B cell-derived ma-
lignancies found involves transcription factors shown to im-
part skewing toward B-cell acute lymphoid leukemia de-
velopment (54,55). It is possible that B cell tumorigene-
sis is unrelated to the viability defect of Rad18−/− LSK
cells and is related to DMBA-sensitivity of B lineage-
committed progenitor cells rather than multipotent pro-
genitors. Alternatively, multipotent progenitors may be the
primary targets of DMBA-induced genome instability in
Rad18−/− mice, potentially conferring ‘malignant poten-
tial’ of all subsequent lineages. However, T cell-committed
pre-neoplastic cells may die readily, if they are more de-
pendent on Rad18 for survival compared with B cell lin-
eages: pre-neoplastic cells experience considerable stress
during progression to malignancy and B chronic lympho-
cytic leukemia cells are notoriously resistant to DNA dam-
age (56). Therefore, skewing in favor of B cell malignancies
could result if B cell lineages rely less on Rad18 for stress
tolerancewhen comparedwith other hematopoietic progen-
itors. It is likely that carcinogen-induced tumorigenesis is
driven by error-proneTLS and pointmutations inRad18+/+
animals but via replication fork collapse, DSB and the en-
suing translocations whenRad18 is absent. Point mutations
and translocation-based oncogenic events might predispose
to B cell or T cell malignancies, respectively.
Mechanism(s) of FA pathway activation by Rad18
seem to depend on biological context. In response to
bulky DNA lesions, the FA pathway is activated sec-
ondarily to PCNA mono-ubiquitination (10,13), whereas
replication-coupled DSB (in camptothecin-treated cells)
trigger RAD18-mediated FA pathway activation indepen-
dently of PCNA ubiquitination (12). We show that a hall-
mark of FA pathway activation in vivo, namely Fancd2 re-
cruitment to asynaptic chromosomes in spermatocytes is
Rad18-dependent (Figure 7). Recruitment of Rad18 to asy-
naptic chromosomes requires Spo11, the nuclease that gen-
erates DSB during meiosis (not shown). Therefore, mei-
otic regulation of Fancd2 by Rad18 may resemble the
Rad18-dependent (PCNA-independent) activation mecha-
nism that occurs in camptothecin-treated cells. Rad18−/−
and Fanc-deficient mice have defective spermatogenesis and
fertility defects (15,31,57), possibly related to common de-
fects in meiotic processing of DSB.
In conclusion, we show that the Rad18 and FA path-
ways are separable in vivo. Ours is the first demonstration
of a physiological role for Rad18 inDNAdamage tolerance,
HSCmaintenance and suppression of hematological malig-
nancies.
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